Vaidehi Prasanth: IV Iron in Heart Failure – Exploring Hospitalisation Benefits vs. Infection Risk in Open Heart
Vaidehi Prasanth, Senior Resident at All India Institute of Medical Sciences, shared a post on LinkedIn about a recent article by her published in Open Heart, adding:
“Pleased to share our latest publication in Open Heart (BMJ Group):
Infection risk and clinical outcomes with intravenous iron in adults with heart failure and iron deficiency: a systematic review and meta-analysis of randomised controlled trials.
Our review explored an important clinical question: How does intravenous iron affect infection risk alongside its clinical benefits in heart failure?
Key findings:
- Intravenous iron probably reduces first and recurrent heart-failure hospitalisations, with a pooled rate ratio of 0.78 (95% CI 0.67–0.90).
- No clear increase in infection or serious infection was observed. However, low to very low certainty of evidence means that infection safety remains uncertain.
- Intravenous iron probably has little or no effect on all-cause mortality.
An important message from this work is the need for standardised infection definitions and more complete safety reporting in future trials, including both affected participants and recurrent infection episodes.
I am pleased to contribute to research on iron therapy and its role in multidisciplinary patient care. Grateful to my co-authors for their collaboration and shared commitment to this work.”
Title: Infection risk and clinical outcomes with intravenous iron in adults with heart failure and iron deficiency: a systematic review and meta-analysis of randomised controlled trials
Authors: Saikat Mandal, Joyisa Deb, Vaidehi Prasanth, Aswin K Mohan, Justin Jose, So Ahng Yoon, Manideepa Maji, Asmita Goswami, Anindya Mukherjee, Arkadeep Dhali
Stay updated on all scientific advances with Hemostasis Today.
-
Nov 11, 2026, 15:18Stefan Prendić: Can Algorithms Support Antibody Identification in Immunohematology?
-
Nov 11, 2026, 15:12Perioperative Challenges in Hemophilia Patients on Rebalancing Therapies
-
Nov 11, 2026, 15:03Maria Elisa Mancuso: World-Renowned Faculty and 33 Global Participants Unite at Hemophilia Academy 2026
-
Nov 11, 2026, 15:01Hassan Raza: The JAK2 V617F Revolution
-
Nov 11, 2026, 14:57Edward Lee Carter: Factor Xla Inhibition Enters Clinical Practice – FDA Approval of Asundexian
-
Nov 11, 2026, 14:45ITP Is More Than a Platelet Count: Why Patient Perspectives Matter – ITP Australia and New Zealand
-
Nov 11, 2026, 14:27Aswin K Mohan։ Intravenous Iron in Heart Failure and Infection Risk
-
Nov 11, 2026, 14:12Thomas Lund: Advancing Home Treatment in Hematology Across Borders
-
Nov 11, 2026, 14:06Ahmed Alotaibi: The Hidden Iron Deficiency Behind a Normal Haemoglobin